and Media

Investor Overview

Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

  • Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] was approved by the FDA on May 3, 2018. Learn more.
  • Bevyxxa® (betrixaban) was approved by the FDA on June 23, 2017. Learn more.
  • Cerdulatinib – Investigational, oral, dual-spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitior. Portola has worldwide rights to develop and commercialize cerdulatinib. Learn more.
Stock Info
Upcoming Events
No events to display

More ›

Corporate Presentation
Recent News
Sep 19, 2019

Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of...

Aug 22, 2019

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual Biotech Conference on Wednesday,...

Aug 13, 2019

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. In...

More ›

Annual Report